{"prompt": "['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', 'their presence perhaps indicating an underlying significant cancer - even when', 'otherwise classified as low to very low-risk.', '1.4. Exploratory Biomarkers', '1.4.1. PTEN', 'PTEN is a tumor suppressor gene implicated in the tumorigenesis and', 'progression of prostate cancer. 66-69 It plays an important role in the modulation of', 'phosphatidylinositol-3-kinase (PI3K) signaling, most likely though preventing the', 'activation of the protein kinase Akt. 70 Loss or inactivation of PTEN can in turn', 'lead to the upregulation of PI3K/AKT signaling as well as downstream mTOR', 'signaling. 71 Genomic PTEN loss as determined through Fluorescence in situ', 'hybridization (FISH) as well as lost PTEN expression as determined by', 'immunohistochemistry (IHC) have been associated with adverse pathological', 'markers as well as increased risk of recurrence following prostatectomy.72-76', '1.4.2. MYC', 'MYC is an onco-protein that functions as a transcription factor, regulating', 'cell proliferation, metabolism, protein synthesis, mitochondrial function and stem', 'cell renewal.77 Like PTEN, its expression has been associated with prostate', 'cancer initiation and progression. 77-79 Indeed, MYC has been shown to be able', 'to transform benign prostate cancer cells in a single step and its overexpression', 'has been documented at the earliest stages of transformation in prostatic', 'intraepithelial neoplasia samples.', '78,80', 'The region on chromosome 8q24 that', 'encompasses the MYC locus is often altered (e.g. amplified, deleted) in more', 'advanced disease.', '77,81-83 Interestingly, while alterations in chromosome 8q24', 'have been documented in more advanced cases of prostate cancer, MYC protein', 'expression seems to be higher in Gleason 3 disease compared to Gleason 4-5', 'disease.77', '1.4.3. ERG', 'Gene fusions between the androgen receptor regulated TMPRSS2 gene', 'and members of the ETS family of nuclear transcription factors (primarily ERG)', '23', 'Printed on 1/29/2021']['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', 'are frequently recognized in prostate cancer specimens.84 Furthermore, these', 'gene fusions may synergize with PTEN loss, leading to more aggressive prostate', 'cancer behavior. 72,85', '1.4.4. KI-67', 'KI-67 (Ki67) is a nuclear protein complex that is present during all active', 'phases of the cell cycle, but absent during the G0 phase, making it a marker of', 'cellular proliferation [Gerdes et al, 1984].86 In men with localized prostate cancer,', 'Ki67 has been found to independently associate with the risk of developing', 'progressive disease following both radiation therapy and radical', 'prostatectomy. 72,87', '1.4.5. AR-axis liquid biopsy assay', 'Expression of a panel of RNA markers will be evaluated from whole blood', 'collected in PAXgene RNA tubes. These cancerous RNA transcripts are involved', 'in AR-signaling, steroidogenesis, proliferation, neuroendocrine and other', 'pathways important in prostate cancer. Detection of differential expression levels', 'may associate with response to drug treatment.', '1.4.6. Prostate Cancer mRNA Expression Profiling/Risk Classifier', 'There are several commercially available mRNA expression assays', 'designed to assess the risk of prostate cancer recurrence/progression (e.g.,', 'Decipher [GenomeDX Biosciences, San Diego, CA] and Oncotype DX Prostate', 'Cancer Assay [Genomic Health, Inc., Redwood City, CA]).\u00b2 2-6 In addition, whole', 'transcriptome sequencing (i.e., RNA-seq) can provide detailed assessment of the', 'landscape of genes being transcribed within a population of cancer cells, and', 'provide insights into potential resistance mechanisms. One or more of these', 'approaches will be used on prostate core biopsy specimens obtained pre- and', 'post-treatment with apalutamide. The goal will be to develop predictive', 'biomarkers for response to apalutamide.', '24', 'Printed on 1/29/2021']\n\n###\n\n", "completion": "END"}